FP7Индивидуална стипендия2013–2015

Xeno-Autoantibodies · Immune Recognition of Xeno-Glycans

7РП — „Хора“ (Действия „Мария Кюри“)

Период: 2013-03-01 → 2015-02-28
Финансиране от ЕС: 227 231 €
Участници: 1
Схема: MC-IIF

Линиите свързват координатора с партньорите.

Накратко на български

Специфични антитела, разпознаващи чужди за организма захари (гликани), се тестват чрез използването на специални наночастици при мишки. Това помага за разработването на нови терапии, които да стимулират имунната система да атакува раковите клетки.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Immune Recognition of Xeno-Glycans

This project aimed at designing novel therapetics based on xeno-autoantibodies. During the grant period we were able to affinity-purify such antibodeis for further characterization and in addition genered novel glyco-nanoparticles as immunogens to facilitate cancer-associated immune response to xeno-autoglycans in a relevant mouse model. Further studies will further characterize ther therapeutic potential in our mouse cancer model.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

‘xeno-autoantibodies’ recognize a dietary immunogenic non-self sugar that is metabolized by cells as self and presented on the cell surface. N-acetylneuraminic acid (Neu5Ac) and its hydroxylated form, N-glycolylneuraminic acid (Neu5Gc) are the two major Sia forms in most mammals. Humans are deficient in the enzyme CMP-Neu5Ac hydroxylase (CMAH) that can synthesize Neu5Gc, however dietary Neu5Gc accumulates in epithelial tumors and become immunogenic. Our previous research recognized dual and opposing roles of IgG isotype xeno-autoantibodies in cancer progression, diagnosis and immunotherapy: they facilitate tumor progression via chronic inflammation at low doses, but mediate tumor inhibition at higher doses in a ‘human-like’ Cmah-/- Neu5Gc-deficient mouse model. Furthermore, we developed a novel sialoglycan microarray that lead to the discovery of a specific xeno-auto-IgG that is novel human serum carcinoma biomarker and potential immunotherapeutic. However, our early studies also revealed that some human sera show high levels of anti-Neu5Gc IgAs that could even be affinity-purified from human serum (7). IgA is the most abundantly produced antibody isotype in the body and the main isotype in mucosal surfaces; It is also present in serum, where IgG is the predominant isotype. I propose a multidisciplinary approach to investigate the biology of IgA xeno-autoantibodies against these unique glycans and their potential involvement in cancer. I will combine glycobiology, immunology, biochemistry, molecular biology, nanotechnology and advanced array techniques to address these lines of investigation both in vitro and in vivo in a relevant mouse model (Cmah-/-).

Оригинален текст от CORDIS (на английски).

Участници

TEL AVIV UNIVERSITY · Tel AvivКоординаторИзраел

Връзки

Виж в CORDIS